ALGS

Aligos Therapeutics, Inc. NASDAQ Listed Oct 16, 2020

Healthcare ·Biotechnology ·US · aligos.com

$6.03

Mkt Cap $37.3M

52w Low $4.20 19.3% of range 52w High $13.69

50d MA $7.07 200d MA $8.56

P/E (TTM) -2.5x

EV/EBITDA -0.9x

P/B 1.1x

Debt/Equity 0.1x

ROE -45.2%

P/FCF -1.1x

RSI (14) —

ATR (14) —

Beta 2.62

50d MA $7.07

200d MA $8.56

Avg Volume 169.6K

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

SIC Code

2836

CIK (SEC)

1799448

Phone

800 466 6059

One Corporate Drive · South San Francisco, CA 94080 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 5, 2026	AMC	-2.49	-1.91	+23.2%	6.66	-3.9%	+4.8%	+5.6%	+6.6%	+13.7%	+11.3%	—
Nov 6, 2025	AMC	-2.09	-3.04	-45.5%	7.10	-12.4%	-0.4%	-3.0%	-5.9%	-9.0%	-14.5%	—
Aug 6, 2025	AMC	-2.35	-1.53	+34.9%	8.04	-3.9%	+1.1%	-4.4%	-5.8%	-7.5%	-4.9%	—
May 6, 2025	AMC	-2.80	-2.11	+24.6%	4.58	+1.1%	-4.8%	+6.3%	-2.2%	+24.0%	+29.7%	—
Mar 10, 2025	AMC	-2.63	-3.41	-29.7%	10.41	-1.1%	+1.0%	+3.8%	-1.2%	+9.9%	+12.1%	—
Nov 6, 2024	AMC	-2.15	-3.07	-42.8%	9.35	-2.9%	+6.1%	+9.0%	+49.6%	+90.9%	+109.4%	—
Aug 6, 2024	AMC	-4.00	0.75	+118.8%	11.18	+3.9%	+21.9%	+21.9%	+23.0%	+21.2%	+20.6%	—
May 7, 2024	AMC	-4.75	-5.50	-15.8%	19.75	-0.6%	-0.9%	-1.7%	-7.5%	-13.4%	-12.5%	—
Mar 12, 2024	AMC	-6.75	-5.50	+18.5%	21.75	+0.0%	+0.0%	-0.0%	+5.9%	+5.7%	+7.1%	—
Nov 2, 2023	AMC	-12.00	-10.25	+14.6%	18.75	+0.0%	+1.4%	+1.3%	-1.9%	-1.4%	+2.7%	—
Aug 3, 2023	AMC	-12.50	-10.75	+14.0%	22.25	+5.6%	-0.5%	+0.6%	+5.6%	+9.4%	+9.0%	—
May 4, 2023	AMC	-12.25	-13.25	-8.2%	34.00	-5.1%	-8.8%	-9.6%	-9.6%	-11.8%	-17.6%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.10	$7.29	+2.7%	+6.6%	+4.4%	+6.6%	+8.7%	+2.8%
Sep 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.88	$10.71	-1.6%	-6.2%	-13.9%	-17.7%	-15.3%	-8.2%
Mar 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.12	$8.70	-4.6%	-9.5%	-21.7%	-16.9%	-28.9%	-34.8%
Mar 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.41	$10.30	-1.1%	+1.0%	+3.8%	-1.2%	+9.9%	+12.1%
Nov 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.35	$9.08	-2.9%	+6.1%	+9.0%	+49.6%	+90.9%	+109.4%
Oct 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.34	$7.37	+0.4%	-1.8%	+23.0%	+14.4%	+20.8%	+27.5%
Sep 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.18	$10.60	+4.1%	-10.2%	-20.4%	-19.9%	-19.3%	-21.2%
Jan 17	Piper Sandler	Maintains	Overweight → Overweight	—	$41.00	$44.75	+9.1%	+23.2%	+28.7%	+23.8%	+25.6%	+17.7%
Jan 6	Jefferies	Upgrade	Hold → Buy	—	$24.75	$29.50	+19.2%	+32.3%	+31.3%	+59.6%	+65.7%	+45.5%
Jan 6	Piper Sandler	Upgrade	Neutral → Overweight	—	$24.75	$29.50	+19.2%	+32.3%	+31.3%	+59.6%	+65.7%	+45.5%
Nov 3	SVB Leerink	Maintains	Market Perform → Market Perform	—	$26.75	$26.25	-1.9%	-1.9%	-7.5%	-7.9%	-11.9%	-16.5%
May 5	SVB Leerink	Downgrade	Outperform → Market Perform	—	$31.00	$28.50	-8.1%	-11.3%	-16.1%	-11.3%	-6.5%	-12.1%
Mar 23	Piper Sandler	Downgrade	Overweight → Neutral	—	$72.50	$66.75	-7.9%	-3.8%	-18.6%	-21.4%	-27.2%	-26.4%
Mar 23	SVB Leerink	Maintains	Outperform → Outperform	—	$72.50	$66.75	-7.9%	-3.8%	-18.6%	-21.4%	-27.2%	-26.4%
Mar 11	Piper Sandler	Maintains	Overweight → Overweight	—	$61.25	$63.25	+3.3%	+5.7%	+0.0%	-3.7%	+5.3%	+12.2%
Mar 11	SVB Leerink	Maintains	Outperform → Outperform	—	$61.25	$63.25	+3.3%	+5.7%	+0.0%	-3.7%	+5.3%	+12.2%
Feb 16	SVB Leerink	Maintains	Outperform → Outperform	—	$66.00	$66.75	+1.1%	-4.2%	-9.8%	-8.3%	-9.5%	-16.3%
Jan 7	JP Morgan	Downgrade	Overweight → Neutral	—	$114.75	$111.27	-3.0%	-14.8%	-18.7%	-13.5%	-18.1%	-27.5%
Jan 7	SVB Leerink	Maintains	Outperform → Outperform	—	$114.75	$111.27	-3.0%	-14.8%	-18.7%	-13.5%	-18.1%	-27.5%
Sep 9	SVB Leerink	Maintains	Outperform → Outperform	—	$382.75	$387.50	+1.2%	+1.9%	-0.6%	+1.8%	+2.5%	+6.1%
Nov 10	Piper Sandler	Maintains	Overweight → Overweight	—	$449.50	$456.75	+1.6%	-10.8%	-4.5%	-5.3%	+9.6%	+16.3%
Nov 10	JP Morgan	Maintains	Overweight → Overweight	—	$449.50	$456.75	+1.6%	-10.8%	-4.5%	-5.3%	+9.6%	+16.3%
Nov 10	Jefferies	Maintains	Buy → Buy	—	$449.50	$456.75	+1.6%	-10.8%	-4.5%	-5.3%	+9.6%	+16.3%

Data updated apr 24, 2026 5:14pm · Source: massive.com